

Division of Workers' Compensation Pharmacy and Therapeutics Committee

October 16, 2024
12:30pm to 2:30pm



State of California
Gavin Newsom
Governor

Agenda

- **Welcome and Introductions**
George Parisotto, Administrative Director, DWC
- **Physician and Pharmaceutical Fee Schedule Update**
George Parisotto
- **Approval of Minutes from the April 17, 2024 Meeting**
Dr. Raymond Meister, Executive Medical Director, DWC
- **MTUS Drug List v12**
Dr. Raymond Meister
- **Discussion:**
 - MTUS with RxCUI - Updated – *Kevin Gorospe Pharm D, DWC Consultant*
 - MTUS Biosimilars – *Kevin Gorospe Pharm D, DWC Consultant*
 - MTUS Drug Lookup - Updated – *Kevin Gorospe Pharm D, DWC Consultant*
 - MTUS List Use Rates – *Kevin Gorospe Pharm D, DWC Consultant*
- **Additional Public Comments**
- **Review of Committee Recommendations**
- **Adjourn**

Welcome and Introductions

George Parisotto

Administrative Director, DWC

Physician and Pharmaceutical Fee Schedule Update

George Parisotto

Administrative Director, DWC



State of California
Gavin Newsom
Governor

Notice of Proposed Rulemaking Update

- Proposed regulations and associated documents can be viewed at <https://www.dir.ca.gov/dwc/DWCPropRegs/2024/Pharmaceutical-Fee-Schedule/Index.htm>

Approval of Minutes

Dr. Raymond Meister

Executive Medical Director, DWC

MTUS Drug List v12

Dr. Raymond Meister

Executive Medical Director, DWC

MTUS with RxCUI - Updated

J. Kevin Gorospe, PharmD
DWC Consultant



State of California
Gavin Newsom
Governor

Updated Listings

- Added and removed drugs per MTUS v12
- Clean up some errors, e.g. allowed amounts on special fill for liquid opiates had tablet quantities instead of liquid quantities
- Expanded product listing for oxycodone er
 - Broad RxCUI for oxycodone oral previously used incorporated both extended and immediate release products
 - Differences in ACOEM reference guidelines and special fill/peri op allowances made it necessary to expand the list to more specific RxCUIs

Drug Ingredient	Reference Brand Name	Exempt/Non-Exempt*	Special Fill	Peri-Op	Drug Class	Reference in ACOEM Guidelines
oxycodone er	OXYCONTIN	Non-Exempt	Not Applicable	Not Applicable	Analgesics - Opioid	(X) Opioids
oxycodone er	XTAMPA ER	Non-Exempt	Not Applicable	Not Applicable	Analgesics - Opioid	(X) Opioids
oxycodone hcl	ROXICODONE	Non-Exempt	4 days = 10 tablets	4 days = 10 tablets	Analgesics - Opioid	(R, X) Ankle and Foot Disorders (R, X) Cervical and Thoracic Spine Disorders (R, X) Chronic Pain (R, X) Elbow Disorders (R, X) Hand, Wrist, and Forearm Disorders (R, X) Hip and Groin Disorders (R) Knee Disorders (R,X) Low Back Disorders (R,X) Opioids (R) Shoulder

MTUS Biosimilars

J. Kevin Gorospe, PharmD
DWC Consultant



State of California
Gavin Newsom
Governor

Biosimilars on MTUS List

- Listings for biosimilars added or updated
- Two of the listed ingredients have biosimilars
 - adalimumab (HUMIRA)
 - etanercept (ENBREL)
- “interchangeable” added to Reference Brand Name for biosimilars identified as interchangeable per FDA Purple Book
- Pricing for adalimumab retrieved for comparison; etanercept biosimilars not yet in pricing data

Drug Ingredient	Reference Brand Name
adalimumab	HUMIRA
adalimumab-aacf	IDACIO
adalimumab-aaty	YUFLYMA
adalimumab-adaz	HYRIMOZ (interchangeable)
adalimumab-adbm	CYLTEZO (interchangeable)
adalimumab-afzb	ABRILADA (interchangeable)
adalimumab-aqvh	YUSIMRY
adalimumab-atto	AMJEVITA (interchangeable)
adalimumab-bwwd	HADLIMA (interchangeable)
adalimumab-fkjp	HULIO
adalimumab-ryvk	SIMLANDI (interchangeable)
etanercept	ENBREL
etanercept-szss	ERELZI
etanercept-ykro	ETICOVO (interchangeable)

Biosimilar Pricing

- Prices for reference and biosimilars retrieved
- Medi-Cal reference prices were primarily based on Wholesale Acquisition Cost (WAC)
- Spreadsheet showing prices grouped by Dosage (i.e. mg/ml)
 - Kits listed separately
- Potentially a few errors in reported prices; three NDC with prices 10 times that of comparable Dosages

Committee Discussion

Public Comments

MTUS Drug Lookup - Updated

J. Kevin Gorospe, PharmD
DWC Consultant



State of California
Gavin Newsom
Governor

Drug Lookup Tool (revised)

- No change in form factor
- Updated to incorporate changes to MTUS v12
- Working on a different lookup process using an interactive database to improve user interface and backend maintenance

Committee Discussion

Public Comments

MTUS List Use Rates

J. Kevin Gorospe, PharmD
DWC Consultant



State of California
Gavin Newsom
Governor

MTUS List Use Rates

- Claims were aggregated by ingredient, represented as GENERIC NAME, on the provided spreadsheets
- Spreadsheets are separated by provider type, pharmacy and physician
- Each product was identified as matching or not matching an MTUS ingredient
- The aggregation includes all dosage forms and strengths of a particular ingredient, therefore MTUS used products may have slightly higher amounts than if aggregated at more granular level

Pharmacy MTUS Utilization

- Utilization shows that compliance is relatively high at 87% of billed lines, though low when compared to other non-worker compensation insurances which are typically in the mid 90% range
 - High compliance often attributable to patient copayment structures, i.e. high to 100% copayment for non-formulary drugs
- Interestingly, the amount paid for MTUS drugs accounted for only 55% of the total paid
 - Non-MTUS drugs have very high average payment amounts
 - Many are high-cost biological products

Physician MTUS Utilization

- Physician amounts stripped of many billed injectables to limit list to dispensed products. Some injectables (potentially self-administered) were retained.
- MTUS list drug use was high at 96% of billed lines
- The amount paid for MTUS drugs accounted for 80% of the total paid
 - This may be high due to the exclusion of some injectable products that could have been dispensed and not administered

Committee Discussion

Public Comments

Review of Recommendations

Adjournment